Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- Resverlogix Corp
- Target Recruit Count
- 72
- Registration Number
- NCT00768274
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Dallas, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath